{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:02:14Z","timestamp":1768291334781,"version":"3.49.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,9,6]],"date-time":"2014-09-06T00:00:00Z","timestamp":1409961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40272-014-0089-x","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T07:23:56Z","timestamp":1409901836000},"page":"425-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine: A Review in Infants and Children"],"prefix":"10.1007","volume":"16","author":[{"given":"Greg L.","family":"Plosker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,6]]},"reference":[{"issue":"14","key":"89_CR1","first-page":"129","volume":"87","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. Pneumococcal vaccines WHO position paper\u20142012. Wkly Epidemiol Rec. 2012;87(14):129\u201344.","journal-title":"Wkly Epidemiol Rec."},{"issue":"9693","key":"89_CR2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","volume":"374","author":"KL O\u2019Brien","year":"2009","unstructured":"O\u2019Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5\u00a0years: global estimates. Lancet. 2009;374(9693):893\u2013902.","journal-title":"Lancet."},{"issue":"3","key":"89_CR3","first-page":"217","volume":"16","author":"JP Lynch 3rd","year":"2010","unstructured":"Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010;16(3):217\u201325.","journal-title":"Curr Opin Pulm Med."},{"key":"89_CR4","doi-asserted-by":"crossref","unstructured":"Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10).","DOI":"10.1371\/journal.pmed.1000348"},{"issue":"5","key":"89_CR5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1086\/527396","volume":"46","author":"A Forsgren","year":"2008","unstructured":"Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis. 2008;46(5):726\u201331.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"89_CR6","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/165-Supplement_1-S49","volume":"165","author":"KE Stein","year":"1992","unstructured":"Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis. 1992;165(Suppl 1):S49\u201352.","journal-title":"J Infect Dis."},{"issue":"18","key":"89_CR7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","volume":"348","author":"CG Whitney","year":"2003","unstructured":"Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737\u201346.","journal-title":"N Engl J Med."},{"key":"89_CR8","unstructured":"World Health Organization. WHO\/Health Canada consultation on serological criteria for evaluation and licensing of new pneumococcal vaccines. 7\u20138 July 2008. http:\/\/www.who.int\/biologicals\/publications\/meetings\/areas\/vaccines\/pneumococcal\/en\/index.html . Accessed 29 April 2014."},{"key":"89_CR9","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines. 23 April 2010. http:\/\/www.who.int\/biologicals\/areas\/vaccines\/pneumo\/Pneumo_final_23APRIL_2010.pdf . Accessed 30 April 2014."},{"key":"89_CR10","unstructured":"European Medicines Agency. Synflorix: summary of product characteristics. 25 April 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000973\/WC500054346.pdf . Accessed 27 August 2014."},{"issue":"5","key":"89_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/11202760-000000000-00000","volume":"11","author":"JD Croxtall","year":"2009","unstructured":"Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr Drugs. 2009;11(5):349\u201357.","journal-title":"Paediatr Drugs."},{"issue":"3","key":"89_CR12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/CVI.13.3.356-360.2006","volume":"13","author":"I Henckaerts","year":"2006","unstructured":"Henckaerts I, Goldblatt D, Ashton L, et al. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13(3):356\u201360.","journal-title":"Clin Vaccine Immunol."},{"issue":"Suppl","key":"89_CR13","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","volume":"28","author":"T Vesikari","year":"2009","unstructured":"Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(Suppl):S66\u201376.","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"89_CR14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40272-013-0047-z","volume":"15","author":"GL Plosker","year":"2013","unstructured":"Plosker GL. 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents. Paediatr Drugs. 2013;15(5):403\u201323.","journal-title":"Paediatr Drugs."},{"issue":"6","key":"89_CR15","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/INF.0b013e3181dffabf","volume":"29","author":"T Vesikari","year":"2010","unstructured":"Vesikari T, Karvonen A, Lindblad N, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J. 2010;29(6):e47\u201356.","journal-title":"Pediatr Infect Dis J."},{"issue":"4 Suppl","key":"89_CR16","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/INF.0b013e318199f609","volume":"28","author":"J Wysocki","year":"2009","unstructured":"Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28(4 Suppl):S77\u201388.","journal-title":"Pediatr Infect Dis J."},{"issue":"1","key":"89_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/INF.0b013e3181f2da06","volume":"30","author":"N Bermal","year":"2011","unstructured":"Bermal N, Szenborn L, Edison A, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV\/Hib and poliovirus vaccines. Pediatr Infect Dis J. 2011;30(1):69\u201372.","journal-title":"Pediatr Infect Dis J."},{"issue":"9698","key":"89_CR18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","volume":"374","author":"R Prymula","year":"2009","unstructured":"Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374(9698):1339\u201350.","journal-title":"Lancet."},{"issue":"2","key":"89_CR19","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1542\/peds.2010-1184","volume":"128","author":"F Omenaca","year":"2011","unstructured":"Omenaca F, Merino JM, Tejedor J-C, et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics. 2011;128(2):e290\u20138.","journal-title":"Pediatrics."},{"key":"89_CR20","doi-asserted-by":"crossref","unstructured":"van den Bergh MR, Spijkerman J, Francois N, et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in the Netherlands: a randomized controlled trial. Pediatr Infect Dis J. 2011;e170\u20138.","DOI":"10.1097\/INF.0b013e31821a0614"},{"issue":"11","key":"89_CR21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4161\/hv.7.11.17984","volume":"7","author":"GM Ruiz-Palacios","year":"2011","unstructured":"Ruiz-Palacios GM, Guerrero ML, Hernandez-Delgado L, et al. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccin. 2011;7(11):1137\u201345.","journal-title":"Hum Vaccin."},{"issue":"1","key":"89_CR22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/INF.0b013e3182784143","volume":"32","author":"GM Ruiz-Palacios","year":"2013","unstructured":"Ruiz-Palacios GM, Huang L-M, Lin T-Y, et al. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial. Pediatr Infect Dis J. 2013;32(1):62\u201371.","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"89_CR23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4161\/hv.19287","volume":"8","author":"S Lalwani","year":"2012","unstructured":"Lalwani S, Chatterjee S, Chhatwal J, et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV\/Hib vaccine in Indian infants: a single-blind, randomized, controlled study. Hum Vaccin Immunother. 2012;8(5):612\u201322.","journal-title":"Hum Vaccin Immunother."},{"key":"89_CR24","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/1471-2458-11-882","volume":"11","author":"A Dicko","year":"2011","unstructured":"Dicko A, Odusanya OO, Diallo AI, et al. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health. 2011;11:882.","journal-title":"BMC Public Health."},{"issue":"2","key":"89_CR25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4161\/hv.22692","volume":"9","author":"A Dicko","year":"2013","unstructured":"Dicko A, Santara G, Mahamar A, et al. Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children. Hum Vaccin Immunother. 2013;9(2):382\u20138.","journal-title":"Hum Vaccin Immunother."},{"issue":"5","key":"89_CR26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4161\/hv.7.5.14634","volume":"7","author":"RE Lagos","year":"2011","unstructured":"Lagos RE, Munoz AE, Levine MM, et al. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Hum Vaccin. 2011;7(5):511\u201322.","journal-title":"Hum Vaccin."},{"issue":"9","key":"89_CR27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jfma.2011.07.014","volume":"111","author":"T-Y Lin","year":"2012","unstructured":"Lin T-Y, Lu C-Y, Chang L-Y, et al. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan. J Formos Med Assoc. 2012;111(9):495\u2013503.","journal-title":"J Formos Med Assoc."},{"issue":"6","key":"89_CR28","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","volume":"11","author":"MW Tregnaghi","year":"2014","unstructured":"Tregnaghi MW, Saez-Llorens X, Lopez P, et al. Efficacy of pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657.","journal-title":"PLoS Med."},{"issue":"12","key":"89_CR29","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/INF.0b013e31822a8541","volume":"30","author":"C-H Kim","year":"2011","unstructured":"Kim C-H, Kim JS, Cha S-H, et al. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J. 2011;30(12):e235\u201343.","journal-title":"Pediatr Infect Dis J."},{"key":"89_CR30","unstructured":"Madhi SA, Koen A, Jose L, et al. Primary vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine [PHiD-CV] in HIV-exposed-infected, exposed-uninfected and unexposed-uninfected South African infants (abstract no. 756). In: European Society for Paediatric Infectious Diseases, 8\u201312 May 2012, Thessaloniki."},{"issue":"3","key":"89_CR31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00006454-200203000-00003","volume":"21","author":"H Shinefield","year":"2002","unstructured":"Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002;21(3):182\u20136.","journal-title":"Pediatr Infect Dis J."},{"issue":"4","key":"89_CR32","doi-asserted-by":"crossref","first-page":"e804","DOI":"10.1542\/peds.2006-2094","volume":"119","author":"BE Mahon","year":"2007","unstructured":"Mahon BE, Ehrenstein V, Norgaard M, et al. Perinatal risk factors for hospitalization for pneumococcal disease in childhood: a population-based cohort study. Pediatrics. 2007;119(4):e804\u201312.","journal-title":"Pediatrics."},{"key":"89_CR33","doi-asserted-by":"crossref","unstructured":"Saari TN. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics. 2003;112(1 Pt 1):193\u20138.","DOI":"10.1542\/peds.112.1.193"},{"issue":"10","key":"89_CR34","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/INF.0b013e3181b48ca3","volume":"28","author":"SA Silfverdal","year":"2009","unstructured":"Silfverdal SA, Hogh B, Bergsaker MR, et al. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Pediatr Infect Dis J. 2009;28(10):e276\u201382.","journal-title":"Pediatr Infect Dis J."},{"key":"89_CR35","unstructured":"Vesikari T, Forsten A, Seppa I, et al. Functional antibody responses after 2\u00a0+\u00a01 or 3\u00a0+\u00a01 infant vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHID-CV) (abstract no. ISPPD-0146). In: 9th International Symposium on Pneumococci and Pneumococcal Diseases, 9\u201313 March 2014, Hyderabad."},{"issue":"8","key":"89_CR36","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/INF.0b013e31821d1790","volume":"30","author":"T Vesikari","year":"2011","unstructured":"Vesikari T, Karvonen A, Korhonen T, et al. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine when administered as catch-up vaccination to children 7\u00a0months to 5\u00a0years of age. Pediatr Infect Dis J. 2011;30(8):e130\u201341.","journal-title":"Pediatr Infect Dis J."},{"key":"89_CR37","unstructured":"Silfverdal SA, Prymula R, Traskine M, et al. Immunogenicity\/reactogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) during fourth year (abstract no. 219). In: 8th International Symposium on Pneumococci and Pneumococcal Diseases, 11\u201315 March 2012, Iguacu Falls."},{"issue":"1","key":"89_CR38","doi-asserted-by":"crossref","first-page":"e85459","DOI":"10.1371\/journal.pone.0085459","volume":"9","author":"LL Hammitt","year":"2014","unstructured":"Hammitt LL, Ojal J, Bashraheil M, et al. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1\u20134\u00a0years: a randomized controlled trial. PLoS One. 2014;9(1):e85459.","journal-title":"PLoS One."},{"issue":"9","key":"89_CR39","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e31821feeb7","volume":"30","author":"SA Silfverdal","year":"2011","unstructured":"Silfverdal SA, Skerlikova H, Zanova M, et al. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life. Pediatr Infect Dis J. 2011;30(9):e155\u201363.","journal-title":"Pediatr Infect Dis J."},{"issue":"16","key":"89_CR40","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.vaccine.2013.01.044","volume":"31","author":"R Prymula","year":"2013","unstructured":"Prymula R, Habib A, Francois N, et al. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine. 2013;31(16):2080\u20138.","journal-title":"Vaccine."},{"issue":"9862","key":"89_CR41","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","volume":"381","author":"AA Palmu","year":"2013","unstructured":"Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214\u201322.","journal-title":"Lancet."},{"key":"89_CR42","author":"AA Palmu","year":"2014","unstructured":"Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. Lancet Respir Med. 2014. doi: 10.1016\/S2213-2600(14)70139-0 .","journal-title":"Lancet Respir Med."},{"key":"89_CR43","unstructured":"Palmu AA, Jokinen J, Ruokokoski E, et al. Indirect impact of pneumococcal Haemophilus influenzae protein-D conjugate vaccine (PHID-CV10) on suspected non-confirmed invasive pneumococcal disease (IPD) in cluster-randomized trial (abstract no. ISPPD-0463). Pneumonia. 2014;3:186."},{"key":"89_CR44","doi-asserted-by":"crossref","unstructured":"Mrkvan T, Hausdorff WP, Moreira M, et al. Evidence of early herd protection after infant vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV): a review (abstract no. P6). In: Nordic Vaccine Meeting, 23\u201325 April 2014, Bergen.","DOI":"10.1016\/S0924-8579(13)70604-6"},{"issue":"6","key":"89_CR45","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","volume":"2","author":"CM Domingues","year":"2014","unstructured":"Domingues CM, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case\u2013control study. Lancet Respir Med. 2014;2(6):464\u201371.","journal-title":"Lancet Respir Med"},{"key":"89_CR46","unstructured":"Deceuninck G, Lefebvre B, Bouilanne N, et al. Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease with a 3 (2\u00a0+\u00a01) dose schedule: results of a case control study in Quebec, Canada (poster no. P-271). In: 9th International Symposium on Pneumococci and Pneumococcal Diseases, Hyderabad, 9\u201313 March 2014. http:\/\/isppd.meetingxpert.net\/swf\/poster_viewer.aspx?ID=90654 . Accessed 30 July 2014."},{"key":"89_CR47","unstructured":"Rinta-Kokko H, Jokinen J, Siira L, et al. Impact of 10-valent pneumococcal conjugate vaccine (PCV10) against invasive pneumococcal disease (IPD) among vaccine-eligible children in Finland (abstract). In: European Society for Paediatric Infectious Diseases; 28 May\u20131 June 2013, Milan."},{"key":"89_CR48","unstructured":"Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of 10-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD) among vaccine-eligible children in Finland (abstract). In: 8th World Congress of the World Society for Pediatric Infectious Diseases (WSPID), 19\u201322 November 2013, Capetown."},{"key":"89_CR49","first-page":"171","volume":"3","author":"WP Hausdorff","year":"2014","unstructured":"Hausdorff WP, Mrkvan T, Moreira M, et al. Five years of post-licensure experience with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV): a review (abstract no. ISPPD-0393). Pneumonia. 2014;3:171.","journal-title":"Pneumonia"},{"key":"89_CR50","doi-asserted-by":"crossref","unstructured":"Kilpi T, Palum AA, Puumalainen T, et al. Effectiveness of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against hospital-diagnosed pneumonia in infants\u2014FinIP trial (abstract). In: European Society for Paediatric Infectious Diseases; 28 May\u20131 June 2013, Milan.","DOI":"10.1016\/S0140-6736(12)61854-6"},{"key":"89_CR51","unstructured":"Zhou Z, Deceuninck G, Boucher F, et al. Impact of two pneumococcal conjugate vaccines on hospitalizations for lower-tract respiratory infections (LTRI) in Quebec, Canada (abstract no. ISPPD-0335). Pneumonia. 2014;3:259."},{"issue":"4","key":"89_CR52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3201\/eid1904.121198","volume":"19","author":"ET Afonso","year":"2013","unstructured":"Afonso ET, Minamisava R, Bierrenbach AL, et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis. 2013;19(4):589\u201397.","journal-title":"Emerg Infect Dis."},{"issue":"35","key":"89_CR53","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1016\/j.vaccine.2014.06.042","volume":"32","author":"MC Scotta","year":"2014","unstructured":"Scotta MC, Veras TN, Klein PC, et al. Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction. Vaccine. 2014;32(35):4495\u20139.","journal-title":"Vaccine."},{"key":"89_CR54","unstructured":"Minamisava R, Sgambati S, Morais-Neto OL, et al. Impact of PCV10 introduction on pneumonia mortality rates in Brazil: a time series analysis (abstract no. ISPPD-0556). Pneumonia. 2014;3:248."},{"key":"89_CR55","unstructured":"Sigurdsson S, Kristinsson KG, Erlendsdottir H, et al. An early reduction of acute otitis media and pneumonia in children in Iceland following PCV-10 immunization (abstract). In: European Society for Paediatric Infectious Diseases, 6\u201310 May 2014, Dublin."},{"issue":"9512","key":"89_CR56","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0140-6736(06)68304-9","volume":"367","author":"R Prymula","year":"2006","unstructured":"Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006;367(9512):740\u20138.","journal-title":"Lancet."},{"key":"89_CR57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1473-3099(13)70338-4","volume":"14","author":"AA Palmu","year":"2014","unstructured":"Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3\u20134 trial. Lancet Infect Dis. 2014;14:205\u201312.","journal-title":"Lancet Infect Dis."},{"key":"89_CR58","unstructured":"Sartori AL, Minamisava R, Afonso ET, et al. Reduction in all-cause otitis-related outpatient visits in children after PCV10 introduction in Brazil (abstract no. ISPPD-0244). Pneumonia. 2014;3:240 (plus poster no. P-417 presented at the 9th International Symposium on Pneumococci and Pneumococcal Diseases; 9\u201313 March 2014, Hyderabad)."},{"key":"89_CR59","unstructured":"Jokinen J, Kilpi TM, Kaijalainen T, et al. Indirect effectiveness of pneumococcal Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV10) against oropharyngeal and nasopharyngeal carriage\u2014FinIP indirect carriage study (abstract no. ISPPD-0395). Pneumonia. 2014;3:13."},{"key":"89_CR60","unstructured":"Vesikari T, Forsten A, Seppa I, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage in Finnish children: a cluster-randomized controlled trial (abstract). In: 23rd European Congress of Clinical Microbiology and Infectious Diseases, 27\u201330 April 2013, Berlin."},{"key":"89_CR61","unstructured":"GlaxoSmithKline. COMPAS results summary (study 109563). 2014. http:\/\/www.gsk-clinicalstudyregister.com\/study\/109563?csrf_token=1406243184.07%23%233dee65e28d6a379099b43d253d3b17c144a135f5&search_terms=COMPAS&titles=&study_ids=&study_type=&document_type=&recruitment=&conditions=&compounds=&lead=&collaborators=&gender=&patient_level_data=&age_from=&age_from_type=&age_to=&age_to_type=&first_receive_from=&first_receive_to=&last_updated_from=&last_updated_to=&country=&state=&search=Search#rs . Accessed 25 July 2014."},{"issue":"6","key":"89_CR62","doi-asserted-by":"crossref","first-page":"e98128","DOI":"10.1371\/journal.pone.0098128","volume":"9","author":"AL Andrade","year":"2014","unstructured":"Andrade AL, Ternes YM, Vieira MA, et al. Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil. PLoS One. 2014;9(6):e98128.","journal-title":"PLoS One."},{"key":"89_CR63","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2214-109X(14)70224-4","volume":"2","author":"LL Hammitt","year":"2014","unstructured":"Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health. 2014;2:e397\u2013405.","journal-title":"Lancet Glob Health."},{"issue":"10","key":"89_CR64","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.vaccine.2010.12.086","volume":"29","author":"R Prymula","year":"2011","unstructured":"Prymula R, Hanovcova I, Splino M, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine. 2011;29(10):1959\u201367.","journal-title":"Vaccine."},{"issue":"3","key":"89_CR65","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1093\/cid\/cis922","volume":"56","author":"MR Bergh van den","year":"2013","unstructured":"van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56(3):e30\u20139.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"89_CR66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.vaccine.2009.09.113","volume":"28","author":"R Prymula","year":"2010","unstructured":"Prymula R, Kriz P, Kaliskova E, et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2\u00a0years of age. Vaccine. 2010;28(1):71\u20138.","journal-title":"Vaccine."},{"issue":"4 Suppl","key":"89_CR67","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/INF.0b013e318199f62d","volume":"28","author":"B Chevallier","year":"2009","unstructured":"Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009;28(4 Suppl):S109\u201318.","journal-title":"Pediatr Infect Dis J."},{"issue":"29","key":"89_CR68","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1016\/j.vaccine.2014.04.066","volume":"32","author":"AN Torne","year":"2014","unstructured":"Torne AN, Dias JG, Quinten C, et al. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine. 2014;32(29):3644\u201350.","journal-title":"Vaccine."},{"issue":"51","key":"89_CR69","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1016\/j.vaccine.2013.05.042","volume":"31","author":"SR Santos dos","year":"2013","unstructured":"dos Santos SR, Passadore LF, Takagi EH, et al. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation. Vaccine. 2013;31(51):6150\u20134.","journal-title":"Vaccine."},{"issue":"4","key":"89_CR70","doi-asserted-by":"crossref","first-page":"e1001017","DOI":"10.1371\/journal.pmed.1001017","volume":"8","author":"S Flasche","year":"2011","unstructured":"Flasche S, Van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 2011;8(4):e1001017.","journal-title":"PLoS Med."},{"key":"89_CR71","doi-asserted-by":"crossref","unstructured":"Weil-Olivier C, van der Linden M, de Schutter I, et al. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12(207).","DOI":"10.1186\/1471-2334-12-207"},{"issue":"6","key":"89_CR72","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.vaccine.2010.12.021","volume":"29","author":"APDO Menezes","year":"2011","unstructured":"Menezes APDO, Campos LC, dos Santos MS, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000\u20132007. Vaccine. 2011;29(6):1139\u201344.","journal-title":"Vaccine."},{"issue":"3","key":"89_CR73","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.ijid.2009.05.010","volume":"14","author":"DJ Isaacman","year":"2010","unstructured":"Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14(3):e197\u2013209.","journal-title":"Int J Infect Dis."},{"issue":"3","key":"89_CR74","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1542\/peds.2008-1702","volume":"125","author":"SL Kaplan","year":"2010","unstructured":"Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429\u201336.","journal-title":"Pediatrics."},{"issue":"48","key":"89_CR75","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1016\/j.vaccine.2010.07.053","volume":"28","author":"TY Lin","year":"2010","unstructured":"Lin TY, Shah NK, Brooks D, et al. Summary of invasive pneumococcal disease burden among children in the Asia\u2013Pacific region. Vaccine. 2010;28(48):7589\u2013605.","journal-title":"Vaccine."},{"issue":"3","key":"89_CR76","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa0800836","volume":"360","author":"HE Hsu","year":"2009","unstructured":"Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244\u201356.","journal-title":"N Engl J Med."},{"issue":"12","key":"89_CR77","doi-asserted-by":"crossref","first-page":"20750","DOI":"10.2807\/1560-7917.ES2014.19.12.20750","volume":"19","author":"SI Aguiar","year":"2014","unstructured":"Aguiar SI, Brito MJ, Horacio AN, et al. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18\u00a0years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012. Euro Surveill. 2014;19(12):20750.","journal-title":"Euro Surveill."},{"issue":"6","key":"89_CR78","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S2213-2600(14)70076-1","volume":"2","author":"G Rodgers","year":"2014","unstructured":"Rodgers G. Prevention of invasive pneumococcal disease: new evidence. Lancet Respir Med. 2014;2(6):432\u20134.","journal-title":"Lancet Respir Med."},{"issue":"6","key":"89_CR79","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/S2213-2600(14)70128-6","volume":"2","author":"CJ Clarke","year":"2014","unstructured":"Clarke CJ, Hausdorff WP. Further evidence for the effectiveness of PCV10 against Streptococcus pneumoniae serotype 19A. Lancet Respir Med. 2014;2(6):e7.","journal-title":"Lancet Respir Med."},{"key":"89_CR80","author":"NJ Andrews","year":"2014","unstructured":"Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014. doi: 10.1016\/S1473-3099(14)70822-9 .","journal-title":"Lancet Infect Dis."},{"issue":"9546","key":"89_CR81","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","volume":"368","author":"CG Whitney","year":"2006","unstructured":"Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case\u2013control study. Lancet. 2006;368(9546):1495\u2013502.","journal-title":"Lancet."},{"issue":"52","key":"89_CR82","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.1016\/j.vaccine.2011.10.012","volume":"29","author":"E Grimprel","year":"2011","unstructured":"Grimprel E, Laudat F, Patterson S, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine. 2011;29(52):9675\u201383.","journal-title":"Vaccine."},{"key":"89_CR83","unstructured":"Nuorti JP, Rinta-Kokko H, Toropainen M, et al. Invasive pneumococcal disease among adults after routine infant conjugate vaccination in Finland\u2014implications for vaccination policy (abstract no. ISPPD-0234). In: 9th International Symposium on Pneumococci and Pneumococcal Diseases, 9\u201313 March 2014, Hyderabad."},{"issue":"50","key":"89_CR84","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1016\/j.vaccine.2012.10.017","volume":"30","author":"AJ Hoek van","year":"2012","unstructured":"van Hoek AJ, Choi YH, Trotter C, et al. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30(50):7205\u201313.","journal-title":"Vaccine."},{"issue":"47","key":"89_CR85","doi-asserted-by":"crossref","first-page":"8564","DOI":"10.1016\/j.vaccine.2011.09.025","volume":"29","author":"B Robberstad","year":"2011","unstructured":"Robberstad B, Frostad CR, Akselsen PE, et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011;29(47):8564\u201374.","journal-title":"Vaccine."},{"key":"89_CR86","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1472-6963-12-386","volume":"12","author":"M Bakir","year":"2012","unstructured":"Bakir M, Turel O, Topachevskyi O. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model. BMC Health Serv Res. 2012;12:386.","journal-title":"BMC Health Serv Res."},{"key":"89_CR87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clinthera.2011.12.007","volume":"34","author":"A By","year":"2012","unstructured":"By A, Sobocki P, Forsgren A. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther. 2012;34:177\u201389.","journal-title":"Clin Ther."},{"key":"89_CR88","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jinf.2011.10.015","volume":"64","author":"DR Strutton","year":"2012","unstructured":"Strutton DR, Farkouh RA, Earnshaw SR, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect. 2012;64:54\u201367.","journal-title":"J Infect."},{"key":"89_CR89","doi-asserted-by":"crossref","first-page":"c2509","DOI":"10.1136\/bmj.c2509","volume":"340","author":"MH Rozenbaum","year":"2010","unstructured":"Rozenbaum MH, Sanders EAM, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509.","journal-title":"BMJ."},{"issue":"2","key":"89_CR90","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clinthera.2012.12.006","volume":"35","author":"RM Klok","year":"2013","unstructured":"Klok RM, Lindkvist R-M, Ekelund M, et al. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin Ther. 2013;35(2):119\u201334.","journal-title":"Clin Ther."},{"key":"89_CR91","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2334-12-101","volume":"12","author":"SR Earnshaw","year":"2012","unstructured":"Earnshaw SR, McDade CL, Zanotti G, et al. Cost-effectiveness of 2\u00a0+\u00a01 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis. 2012;12:101.","journal-title":"BMC Infect Dis."},{"issue":"1","key":"89_CR92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1478-7547-11-21","volume":"11","author":"SG Marti","year":"2013","unstructured":"Marti SG, Colantonio L, Bardach A, et al. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc. 2013;11(1):21.","journal-title":"Cost Eff Resour Alloc."},{"issue":"6","key":"89_CR93","doi-asserted-by":"crossref","first-page":"e67324","DOI":"10.1371\/journal.pone.0067324","volume":"8","author":"P Ayieko","year":"2013","unstructured":"Ayieko P, Griffiths UK, Ndiritu M, et al. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLoS One. 2013;8(6):e67324.","journal-title":"PLoS One."},{"issue":"26","key":"89_CR94","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1016\/j.vaccine.2013.03.047","volume":"31","author":"W Kulpeng","year":"2013","unstructured":"Kulpeng W, Leelahavarong P, Rattanavipapong W, et al. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013;31(26):2839\u201347.","journal-title":"Vaccine."},{"issue":"Suppl 6","key":"89_CR95","doi-asserted-by":"crossref","first-page":"G23","DOI":"10.1016\/j.vaccine.2010.06.016","volume":"28","author":"SE Talbird","year":"2010","unstructured":"Talbird SE, Taylor TN, Knoll S, et al. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010;28(Suppl 6):G23\u20139.","journal-title":"Vaccine."},{"issue":"38","key":"89_CR96","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1016\/j.vaccine.2011.06.091","volume":"29","author":"KR Tyo","year":"2011","unstructured":"Tyo KR, Rosen MM, Zeng W, et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011;29(38):6686\u201394.","journal-title":"Vaccine."},{"issue":"31","key":"89_CR97","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.vaccine.2011.04.111","volume":"29","author":"A Uruena","year":"2011","unstructured":"Uruena A, Pippo T, Betelu MS, et al. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine. 2011;29(31):4963\u201372.","journal-title":"Vaccine."},{"key":"89_CR98","doi-asserted-by":"crossref","unstructured":"Lee KKC, Chia Wu DB, Topachevskyi O, et al. The health economic impact of universal infant vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as compared with 13-valent pneumococcal conjugate vaccine in Hong Kong. Value Health Reg Issues. 2013;2(1):64\u201374.","DOI":"10.1016\/j.vhri.2013.01.012"},{"issue":"3","key":"89_CR99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/jech.2010.111880","volume":"66","author":"AMC Sartori","year":"2012","unstructured":"Sartori AMC, de Soarez PC, Novaes HMD. Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil. J Epidemiol Commun Health. 2012;66(3):210\u20137.","journal-title":"J Epidemiol Commun Health."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-014-0089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-014-0089-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-014-0089-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T17:54:29Z","timestamp":1565805269000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-014-0089-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,6]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["89"],"URL":"https:\/\/doi.org\/10.1007\/s40272-014-0089-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,6]]}}}